Next Article in Journal
Inhibition of Uterine Contractility by Thalidomide Analogs via Phosphodiesterase-4 Inhibition and Calcium Entry Blockade
Next Article in Special Issue
Synthetic Strategies for Peroxide Ring Construction in Artemisinin
Previous Article in Journal
Synthesis of Thioethers by InI3-Catalyzed Substitution of Siloxy Group Using Thiosilanes
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Molecules 2016, 21(10), 1331; doi:10.3390/molecules21101331

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

1,2,†
,
2,†
,
2
,
3
and
1,*
1
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2
Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
3
School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
These authors contributed equally to this work
*
Author to whom correspondence should be addressed.
Received: 5 September 2016 / Accepted: 30 September 2016 / Published: 7 October 2016
(This article belongs to the Special Issue Artemisinin: Against Malaria, Cancer and Viruses)
View Full-Text   |   Download PDF [1152 KB, uploaded 12 October 2016]   |  

Abstract

Preclinical investigation and clinical experience have provided evidence on the potential anticancer effect of artemisinin and its derivatives (ARTs) in the recent two decades. The major mechanisms of action of ARTs may be due to toxic-free radicals generated by an endoperoxide moiety, cell cycle arrest, induction of apoptosis, and inhibition of tumor angiogenesis. It is very promising that ARTs are expected to be a new class of antitumor drugs of wide spectrum due to their detailed information regarding efficacy and safety. For developing repurposed drugs, many other characteristics of ARTs should be studied, including through further investigations on possible new pathways of anticancer effects, exploration on efficient and specific drug delivery systems-especially crossing biological barriers, and obtaining sufficient data in clinical trials. The aim of this review is to highlight these achievements and propose the potential strategies to develop ARTs as a new class of cancer therapeutic agents. View Full-Text
Keywords: artemisinin; anticancer activity; repurposed; specific drug delivery system; clinical trials artemisinin; anticancer activity; repurposed; specific drug delivery system; clinical trials
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Li, Z.; Li, Q.; Wu, J.; Wang, M.; Yu, J. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do? Molecules 2016, 21, 1331.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top